Home » Topics » Science » Drug design, drug delivery and technologies

Drug design, drug delivery and technologies
RSS

International team identifies selective P2X antagonists

Aug. 21, 1998

MorphoSys and Pharmacia & Upjohn suspend joint research program

Aug. 20, 1998

Genzyme division and Bayer enter into genomics agreement

Aug. 20, 1998

Genome Therapeutics and Cadus join forces in the search for new therapeutic targets

Aug. 19, 1998

Matrix granted Japanese patent; U.S. patent reissued

Aug. 18, 1998

MorphoSys and DuPont Pharmaceuticals sign collaboration agreement

Aug. 14, 1998

Fusion protein enables large-scale production of bioactive carbohydrates

Aug. 14, 1998

Idun to license patent application for apoptosis model

Aug. 13, 1998

Gene screening technology developed at Harvard Medical School licensed to Versicor

Aug. 10, 1998

Label expansion for CEPRATE SC approved

July 31, 1998

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for July 13, 2026.
FENS 2026: Next-gen biologics take on brain disease
BioWorld
Whether by fine-tuning neurotransmitter signaling or silencing disease-associated genes, emerging biologic therapies are reshaping neuroscience drug development,...
Ionis, AZ shares down on unexpected Wainua flop in cardiomyopathy
BioWorld
News of the unexpected phase III failure of the gene silencing drug Wainua (eplontersen) in the treatment of transthyretin-mediated amyloid cardiomyopathy sent...
Neurovalens granted FDA approval for PTSD therapy for US veterans
BioWorld
Veterans in the U.S. suffering from post-traumatic stress disorder (PTSD) now have access to Neurovalens Ltd.’s Modius Spero, a wearable neuromodulation device,...
NRF2 activators reported in Vailima Peninsula patent
BioWorld Science
Vailima Peninsula Pty Ltd. has discovered new nuclear factor erythroid 2-related factor 2 (NFE2L2; NRF2) activators potentially useful for the treatment of...